This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

55/100

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Blood-based biomarkers offer a major advance in the clinical evaluation of neurodegenerative diseases. Currently, research studies have reported robust assays of blood markers for the detection of amyloid and tau pathologies specific to Alzheimer disease (amyloid-β peptides, and p-tau) and nonspecific blood markers of neuronal (neurofilament light, β-synuclein, and ubiquitin-C-terminal-hydrolase-L1) and glial degeneration (glial fibrillary acidic protein) that can measure key pathophysiologic processes in several neurodegenerative diseases. In the near future, these markers may be used for screening, diagnosis, or disease and treatment response monitoring. Blood-based biomarkers for neurodegenerative diseases have been rapidly implemented in research, and they have the potential to enter clinical use soon in different clinical settings. In this review, we will describe the main developments and their potential implications for the general neurologist.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Alcolea, D., Beeri, M. S., Rojas, J. C., Gardner, R. C., & Lleó, A. (2023). Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist. Neurology. https://doi.org/10.1212/wnl.0000000000207193

Vancouver

Alcolea D, Beeri MS, Rojas JC, Gardner RC, Lleó A. Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist. Neurology. 2023. doi:10.1212/wnl.0000000000207193. PMID: 36878698.

BibTeX

@article{alcolea2023-36878698,
  author  = {Alcolea, D. and Beeri, M. S. and Rojas, J. C. and Gardner, R. C. and Lleó, A.},
  title   = {{Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist}},
  journal = {Neurology},
  year    = {2023},
  doi     = {10.1212/wnl.0000000000207193},
  pmid    = {36878698},
  url     = {https://doi.org/10.1212/wnl.0000000000207193}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Blood-based biomarkers offer a major advance in the clinical evaluation of neurodegenerative diseases.
Currently, research studies have reported robust assays of blood markers for the detection of amyloid and tau pathologies specific to Alzheimer disease (amyloid-β peptides, and p-tau) and nonspecific blood markers of neuronal (neurofilament light, β-synuclein, and ubiquitin-C-terminal-hydrolase-L1) and glial degeneration (glial fibrillary acidic protein) that can measure key pathophysiologic processes in several neurodegenerative diseases.
In the near future, these markers may be used for screening, diagnosis, or disease and treatment response monitoring.
Blood-based biomarkers for neurodegenerative diseases have been rapidly implemented in research, and they have the potential to enter clinical use soon in different clinical settings.
In this review, we will describe the main developments and their potential implications for the general neurologist.

Why it matters

This review describes blood-based biomarkers for amyloid and tau pathology and for neuronal and glial degeneration that may soon be used for screening, diagnosis, or monitoring. It is about biomarkers and does not show that any treatment, cure, or prevention works.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Evidence strengthLow

How this study scored 55/100

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (Neurology)
Journal's citation record	4 / 4	Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	3 / 5	2023 — within 6 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	5 / 7	Cited 117 times (OpenAlex, 2026-10-10)
Citations per year	4 / 5	23.4 citations a year over 5 year(s) since 2023
Impact for its field and year	5 / 6	Cited 21.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	2 / 6	Cited by 5 other studies in this library
Still being cited	3 / 4	Cited 107 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Alberto Lleó: h-index 92 (OpenAlex, whole career)
Institution's track record	2 / 3	University of California, San Francisco: institution h-index 1,915 (OpenAlex)
Multicenter collaboration	2 / 3	OpenAlex lists 8 institution(s) in 3 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 36878698)
Free to read	0 / 2	Behind a paywall — scores zero
Total	55 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

5 studies in the alzhub library list this one in their references.

Related studies in Biomarkers

Also tagged “cerebrospinal”

821 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →